Sahm Adrangi Of Kerrisdale Capital Issues Warning Against Proteostasis Claims
Technology is always advancing, especially in the field of medicine as new cures and treatments are always in the works. Unfortunately, like any other business out there, things are not always what they seem. This looks like the case for a Biotech company that has introduced a new medical treatment for patients to fight cystic fibrosis. Kerrisdale Capital has issued a negative report on said Biotech company with the backing of Sahm Adrangi, Kerrisdale Founder, and CEO. As a leading investment company and one of the most reputable investors in the country, Sahm Adrangi is often heard about and listen to for his insight.
Proteostasis is the Biotech company that Sahm Adrangi is currently calling into question, as he doesn’t believe their medical research was thorough and even reviewed to the maximum extent. Kerrisdale managed to get a closer look into the biotech company and has determined that their research and claims have not be done on an adequate sample sizing since they only had four patients for testing. What Sahm found was that during the trial period for their testing, these four patients experience severe drops in their overall lung performance. With such a small sample size and data that looks sloppy and certainly not finished, Kerrisdale is calling Proteostasis claims into question.
Sahm Adrangi has invested in many companies over the course of his career and to tremendous success because of his insight and deep research protocols. Before investing in a company or letting others know a company is safe, Sahm takes the time to truly dig into a company. This is how he found Proteostasis’s supposed breakthrough was actually much less than what it seemed at the surface. According to the report from Kerrisdale, there are no results to be found through the biotech company’s data. Also, should the biotech company’s drug fail to work, they stand to lose virtually all of their assets, so the desire to produce profits is extremely high. After the initial Kerrisdale report on Proteostasis, the biotech company’s share value fell more than 15 percent.